Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016
JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015
Aggressive Medical Therapy Alone is Not Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2955-2956, Brown, M.M., 2013
Aggressive Medical Therapy Alone is Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2957-2958, Chaturvedi, S.,et al, 2013
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
Ximelagatran--Promises and Concerns
JAMA 293:736-739, Gurewich,V., 2005
Blood Pressure-Lowering for Secondary Prevention of Stroke: ACE Inhibition Is Not the Key
Stroke 34:1334-1335,1335, Bath,P., 2003
Blood Pressure--Lowering for Secondary Prevention of Stroke: ACE Inhibition Is the Key
Stroke 34:1333-1334,1334, Anderson,C., 2003
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
Pharmacologic Treatment of Cognition in Alzheimer's Dementia
Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
HIV Infection-1
BMJ 314:487-491, 579-5831997., Cohn,J.A., 1997
An Update on Primary Drug Therapies for Alzheimer Disease
Arch Neurol 54:1406-1409, Knopman,D.S.&Morris,J.C., 1997
Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents
J Clin Psychiatry 55:38-45, DeVane,C.L., 1994